Featured Research

from universities, journals, and other organizations

Cancer drugs an unexpected ally in the battle against malaria

Date:
April 2, 2013
Source:
Seattle Biomedical Research Institute (Seattle BioMed)
Summary:
Scientists tested the efficacy of cancer drugs at killing the malaria parasite during the liver phase with astonishing success. This research paves the way for future studies using cancer drugs that could cause less drug resistance and have more targeted treatments than conventional malaria drugs.

In the fight against malaria, cancer drugs are far from being considered a useful tool. But new research at Seattle BioMed reveals that liver cells, which are first infected by Plasmodium parasites after their transmission by mosquito bite, actually behave in similar ways to cancer cells. The work also shows that with the help of cancer drugs, the liver can become a hostile environment for the malaria parasite.

This exciting new development is published in this month's issue of the journal Cell Reports.

Humans get malaria by bites from mosquitoes that carry Plasmodium parasites, the most deadly of which is P. falciparum. In malaria research, mouse malaria parasites are frequently used because, like human parasites, they have a "liver phase," in which the parasite first multiplies in the liver and then breaks out into the blood stream to cause disease.

"We knew the malaria parasite goes to the liver, infects liver cells and replicates within them, but we didn't know how it forces the liver cell into submission on a molecular level," says Alexis Kaushansky, lead author and postdoctoral scientist at Seattle BioMed, describing this key stage to the parasite's infectious abilities as a black box.

Kaushansky's background is in cancer biology, so she decided to draw on her strengths to better understand how liver cells were responding to the malaria parasites when she joined the laboratory of Stefan Kappe, professor and director of the malaria program at Seattle BioMed.

One of the challenges to studying the liver phase of malaria is the sheer paucity of infected cells. The liver is a large organ, and the parasites only infect a few cells -- so isolating these cells to study them is extremely difficult, even in mice. As a graduate student, Kaushansky had used systems biology tools to study cancer signaling, and with collaborators Albert Ye and Gavin MacBeath at Harvard Medical School, worked to develop a protein array technology that enabled her to get a large number of read-outs from the few cells she could isolate. Though the technology had been developed in a cancer lab, she eagerly applied it to her work on malaria.

The study yielded a surprising result: many of the molecular changes that malaria parasites cause in infected liver cells are strikingly similar to changes that happen when normal cells transform into cancer cells. But since a liver cell infected with malaria dies when the parasite leaves, there is no characteristic tumor like in liver cancer.

In particular, the malaria parasite dramatically lowers the activity of p53, a classic "tumor-suppressor" in infected cells. This was exciting, since p53 is thoroughly studied in the cancer field, and many cancer drugs are specifically targeted to increase its activity.

Kaushansky and Kappe administered the small molecule Nutlin-3, originally developed as an anti-cancer compound, to mice infected with liver-stage malaria. The cancer drug dramatically reduced malaria infection in the liver, killing 80-90% of the parasite-infected cells.

Using cancer drugs to prevent malaria potentially addresses a key economic challenge in drug creation. Since a vast majority of people who are afflicted with malaria live on less than two dollars a day, developing new drugs, each of which can cost upwards of a billion dollars, can be daunting to pharmaceutical companies who are trying to satisfy shareholders. However, if a drug that has been developed to treat cancer can also be used to prevent malaria, much of the development cost need only to be paid a single time.

Another enticing aspect of using cancer drugs to prevent malaria is that it could avoid the development of drug resistant parasites. All antimalarial drugs currently available for clinical use target the malaria parasite directly, and do so at the peril of a few parasites escaping treatment and rapidly evolving resistance that renders the drugs ineffective. Malaria parasites are even beginning to show signs of resistance to artemisinin, one of the most powerful and affordable malaria drugs currently used in combination therapy. Since the cancer drugs target the non-dividing liver cell rather than the rapidly dividing malaria parasite, there is less opportunity for mutation -- and mutation is what causes drug resistance. For this reason, Kaushansky and Kappe hope their work will provide new opportunities to prevent malaria infection without the occurrence of resistance.

"This is the beginning of a new, exciting research area and much work is needed to bring this to application, including finding liver cell-targeted drug combinations that completely prevent malaria infection," Kappe says. "However, it demonstrates already that new ideas to fight malaria can come from surprising directions, and we must think and work beyond the confines of our study area to come upon the next great discovery."


Story Source:

The above story is based on materials provided by Seattle Biomedical Research Institute (Seattle BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexis Kaushansky, AlbertS. Ye, LauraS. Austin, SebastianA. Mikolajczak, AshleyM. Vaughan, Nelly Camargo, PeterG. Metzger, AlyseN. Douglass, Gavin MacBeath, StefanH.I. Kappe. Suppression of Host p53 Is Critical for Plasmodium Liver-Stage Infection. Cell Reports, 2013; DOI: 10.1016/j.celrep.2013.02.010

Cite This Page:

Seattle Biomedical Research Institute (Seattle BioMed). "Cancer drugs an unexpected ally in the battle against malaria." ScienceDaily. ScienceDaily, 2 April 2013. <www.sciencedaily.com/releases/2013/04/130402090833.htm>.
Seattle Biomedical Research Institute (Seattle BioMed). (2013, April 2). Cancer drugs an unexpected ally in the battle against malaria. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2013/04/130402090833.htm
Seattle Biomedical Research Institute (Seattle BioMed). "Cancer drugs an unexpected ally in the battle against malaria." ScienceDaily. www.sciencedaily.com/releases/2013/04/130402090833.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins